Item Type | Name |
Concept
|
Antigens, Differentiation, T-Lymphocyte
|
Concept
|
B-Lymphocytes
|
Concept
|
T-Lymphocytes, Helper-Inducer
|
Concept
|
Lymphocyte Depletion
|
Concept
|
Lymphocyte Culture Test, Mixed
|
Concept
|
CD4-Positive T-Lymphocytes
|
Concept
|
Lymphocytes, Tumor-Infiltrating
|
Concept
|
Lymphocyte Function-Associated Antigen-1
|
Concept
|
T-Lymphocyte Subsets
|
Concept
|
CD8-Positive T-Lymphocytes
|
Concept
|
Lymphocyte Count
|
Concept
|
T-Lymphocytes, Cytotoxic
|
Concept
|
Receptors, Lymphocyte Homing
|
Concept
|
Lymphocyte Subsets
|
Concept
|
T-Lymphocytes, Regulatory
|
Concept
|
Lymphocyte Activation
|
Concept
|
Lymphocytes
|
Concept
|
T-Lymphocytes
|
Academic Article
|
Differential regulation of murine T lymphocyte subsets.
|
Academic Article
|
Differential function of intestinal intraepithelial lymphocyte subsets.
|
Academic Article
|
B7-1 but not B7-2 efficiently costimulates CD8+ T lymphocytes in the P815 tumor system in vitro.
|
Academic Article
|
Tumor rejection requires a CTLA4 ligand provided by the host or expressed on the tumor: superiority of B7-1 over B7-2 for active tumor immunization.
|
Academic Article
|
Liver of MRL/lpr mice contain interleukin-4-producing lymphocytes and accessory cells that support the proliferation of Th2 helper T lymphocyte clones.
|
Academic Article
|
Induction of a cytolytic T-cell response in mice with a recombinant adenovirus coding for tumor antigen P815A.
|
Academic Article
|
Antigen-specific regression of established tumors induced by active immunization with irradiated IL-12- but not B7-1-transfected tumor cells.
|
Academic Article
|
Antigen recognition and allogeneic tumor rejection in CD8+ TCR transgenic/RAG(-/-) mice.
|
Academic Article
|
The expression of mouse gene P1A in testis does not prevent safe induction of cytolytic T cells against a P1A-encoded tumor antigen.
|
Academic Article
|
Blocked Ras activation in anergic CD4+ T cells.
|
Academic Article
|
Rational development of tumour antigen-specific immunization in melanoma.
|
Academic Article
|
The immune system as anti-tumor sentinel: molecular requirements for an anti-tumor immune response.
|
Academic Article
|
B7-1 engagement of cytotoxic T lymphocyte antigen 4 inhibits T cell activation in the absence of CD28.
|
Academic Article
|
Transgenic expression of the coxsackie/adenovirus receptor enables adenoviral-mediated gene delivery in naive T cells.
|
Academic Article
|
Cutting edge: differentiation of antitumor CTL in vivo requires host expression of Stat1.
|
Academic Article
|
Monitoring specific T-cell responses to melanoma vaccines: ELISPOT, tetramers, and beyond.
|
Academic Article
|
Biochemical analysis of activated T lymphocytes. Protein phosphorylation and Ras, ERK, and JNK activation.
|
Academic Article
|
B7.1 is a quantitatively stronger costimulus than B7.2 in the activation of naive CD8+ TCR-transgenic T cells.
|
Academic Article
|
Antigen-specific blockade of T cells in vivo using dimeric MHC peptide.
|
Academic Article
|
CD28 is not required for c-Jun N-terminal kinase activation in T cells.
|
Academic Article
|
Blockade of T cell activation using a surface-linked single-chain antibody to CTLA-4 (CD152).
|
Academic Article
|
Transplantation and the CD28/CTLA4/B7 pathway.
|
Academic Article
|
Immunization of HLA-A2+ melanoma patients with MAGE-3 or MelanA peptide-pulsed autologous peripheral blood mononuclear cells plus recombinant human interleukin 12.
|
Academic Article
|
Cutting edge: spontaneous rejection of poorly immunogenic P1.HTR tumors by Stat6-deficient mice.
|
Academic Article
|
Differential activation of murine TH1 and TH2 clones.
|
Academic Article
|
Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanoma.
|
Academic Article
|
B7DC/PDL2 promotes tumor immunity by a PD-1-independent mechanism.
|
Academic Article
|
T cell development and function in CrkL-deficient mice.
|
Academic Article
|
Death of peripheral CD8+ T cells in the absence of MHC class I is Fas-dependent and not blocked by Bcl-xL.
|
Academic Article
|
Integrating IL-12 into therapeutic cancer vaccines.
|
Academic Article
|
Absence of CTLA-4 lowers the activation threshold of primed CD8+ TCR-transgenic T cells: lack of correlation with Src homology domain 2-containing protein tyrosine phosphatase.
|
Academic Article
|
Epitope spreading upon P815 tumor rejection triggered by vaccination with the single class I MHC-restricted peptide P1A.
|
Academic Article
|
Clinical responses following nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma are associated with expansion of CD8+ IFN-gamma-producing T cells.
|
Academic Article
|
Differential Ras signaling via the antigen receptor and IL-2 receptor in primary T lymphocytes.
|
Academic Article
|
Cutting edge: targeted ligation of CTLA-4 in vivo by membrane-bound anti-CTLA-4 antibody prevents rejection of allogeneic cells.
|
Academic Article
|
Actin cytoskeleton regulates calcium dynamics and NFAT nuclear duration.
|
Academic Article
|
Depletion of normal B cells with rituximab as an adjunct to IL-2 therapy for renal cell carcinoma and melanoma.
|
Academic Article
|
Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy.
|
Academic Article
|
Gene array and protein expression profiles suggest post-transcriptional regulation during CD8+ T cell differentiation.
|
Academic Article
|
CD4+ murine T cell clones that express high levels of immunoglobulin binding belong to the interleukin 4-producing T helper cell type 2 subset.
|
Academic Article
|
Murine Th1 and Th2 clones proliferate optimally in response to distinct antigen-presenting cell populations.
|
Academic Article
|
Absence of programmed death receptor 1 alters thymic development and enhances generation of CD4/CD8 double-negative TCR-transgenic T cells.
|
Academic Article
|
Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro.
|
Academic Article
|
Evidence implicating utilization of different T cell receptor-associated signaling pathways by TH1 and TH2 clones.
|
Academic Article
|
Cutting edge: cytotoxic granule polarization and cytolysis can occur without central supramolecular activation cluster formation in CD8+ effector T cells.
|
Academic Article
|
Homeostatic proliferation as an isolated variable reverses CD8+ T cell anergy and promotes tumor rejection.
|
Academic Article
|
Immune suppression in the tumor microenvironment.
|
Academic Article
|
Tumor progression despite massive influx of activated CD8(+) T cells in a patient with malignant melanoma ascites.
|
Academic Article
|
Molecular regulation of T-cell anergy.
|
Academic Article
|
The p815 mastocytoma tumor model.
|
Academic Article
|
Production of TH1 and TH2 cell lines and clones.
|
Academic Article
|
Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanoma.
|
Academic Article
|
Homeostatic proliferation plus regulatory T-cell depletion promotes potent rejection of B16 melanoma.
|
Academic Article
|
Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment.
|
Academic Article
|
The HLA-A2-restricted PSMA peptide LLHETDSAV is poorly immunogenic in patients with metastatic prostate cancer.
|
Academic Article
|
Metabolic mechanisms of tumor resistance to T cell effector function.
|
Academic Article
|
Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment.
|
Academic Article
|
Negative regulation of T-cell function by PD-1.
|
Academic Article
|
Peripheral survival of naïve CD8+ T cells.
|
Academic Article
|
Protein kinase Ctheta focusing at the cSMAC is a consequence rather than cause of TCR signaling and is dependent on the MEK/ERK pathway.
|
Academic Article
|
Anti-proliferative effect of IFN-gamma in immune regulation. IV. Murine CTL clones produce IL-3 and GM-CSF, the activity of which is masked by the inhibitory action of secreted IFN-gamma.
|
Academic Article
|
A randomized phase II trial of interleukin-2 in combination with four different doses of bryostatin-1 in patients with renal cell carcinoma.
|
Academic Article
|
Identifying and overcoming immune resistance mechanisms in the melanoma tumor microenvironment.
|
Academic Article
|
Induction of cytotoxic granules in human memory CD8+ T cell subsets requires cell cycle progression.
|
Academic Article
|
Immune resistance orchestrated by the tumor microenvironment.
|
Academic Article
|
Cross-priming of T cells to intracranial tumor antigens elicits an immune response that fails in the effector phase but can be augmented with local immunotherapy.
|
Academic Article
|
Phenotypic and functional analysis of murine CD3+,CD4-,CD8- TCR-gamma delta-expressing peripheral T cells.
|
Academic Article
|
Homeostatic proliferation of naïve CD8+ T cells depends on CD62L/L-selectin-mediated homing to peripheral LN.
|
Academic Article
|
Glucose deprivation inhibits multiple key gene expression events and effector functions in CD8+ T cells.
|
Academic Article
|
Emerging strategies in regulatory T-cell immunotherapies.
|
Academic Article
|
Costimulatory and coinhibitory receptors in anti-tumor immunity.
|
Academic Article
|
Use of Cre-adenovirus and CAR transgenic mice for efficient deletion of genes in post-thymic T cells.
|
Academic Article
|
Evidence implicating the Ras pathway in multiple CD28 costimulatory functions in CD4+ T cells.
|
Academic Article
|
A designer ligand specific for Kv1.3 channels from a scorpion neurotoxin-based library.
|
Academic Article
|
Nakahara memorial lecture. Regulation of T lymphocyte responses: interactions among receptors.
|
Academic Article
|
ICAM-1 contributes to but is not essential for tumor antigen cross-priming and CD8+ T cell-mediated tumor rejection in vivo.
|
Academic Article
|
Glucose availability regulates IFN-gamma production and p70S6 kinase activation in CD8+ effector T cells.
|
Academic Article
|
Evidence implicating I region-restricted antigen presentation in alloantigen and nominal antigen recognition by a dual-reactive helper T lymphocyte clone.
|
Academic Article
|
Murine hepatic accessory cells support the proliferation of Th1 but not Th2 helper T lymphocyte clones.
|
Academic Article
|
Regulation of T-cell activation: differences among T-cell subsets.
|
Academic Article
|
An adenoviral vector for probing promoter activity in primary immune cells.
|
Academic Article
|
Transcriptional regulator early growth response gene 2 (Egr2) is required for T cell anergy in vitro and in vivo.
|
Academic Article
|
Costimulation with B7-1, IL-6, and IL-12 is sufficient for primary generation of murine antitumor cytolytic T lymphocytes in vitro.
|
Academic Article
|
Anti-proliferative effect of IFN-gamma in immune regulation. I. IFN-gamma inhibits the proliferation of Th2 but not Th1 murine helper T lymphocyte clones.
|
Academic Article
|
Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer.
|
Academic Article
|
Differential activation of Th1 and Th2 CD4+ cells by murine brain microvessel endothelial cells and smooth muscle/pericytes.
|
Academic Article
|
Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells.
|
Academic Article
|
Induction of the increased Fyn kinase activity in anergic T helper type 1 clones requires calcium and protein synthesis and is sensitive to cyclosporin A.
|
Academic Article
|
Differential requirement for protein tyrosine kinase Fyn in the functional activation of antigen-specific T lymphocyte clones through the TCR or Thy-1.
|
Academic Article
|
Anergic T-lymphocyte clones have altered inositol phosphate, calcium, and tyrosine kinase signaling pathways.
|
Academic Article
|
Targeting the primary tumor to generate CTL for the effective eradication of spontaneous metastases.
|
Academic Article
|
The expanding universe of regulatory T cell subsets in cancer.
|
Academic Article
|
An adenoviral vector encoding dominant negative Cbl lowers the threshold for T cell activation in post-thymic T cells.
|
Academic Article
|
"Anergy" of TH0 helper T lymphocytes induces downregulation of TH1 characteristics and a transition to a TH2-like phenotype.
|
Academic Article
|
CARMA1 controls an early checkpoint in the thymic development of FoxP3+ regulatory T cells.
|
Academic Article
|
Beta-catenin inhibits T cell activation by selective interference with linker for activation of T cells-phospholipase C-?1 phosphorylation.
|
Academic Article
|
Cellular and molecular requirements for rejection of B16 melanoma in the setting of regulatory T cell depletion and homeostatic proliferation.
|
Academic Article
|
Anti-proliferative effect of IFN-gamma in immune regulation. II. IFN-gamma inhibits the proliferation of murine bone marrow cells stimulated with IL-3, IL-4, or granulocyte-macrophage colony-stimulating factor.
|
Academic Article
|
Interleukin 2 and concanavalin A stimulate interferon-gamma production in a murine cytolytic T cell clone by different pathways.
|
Academic Article
|
Control of T lymphocyte signal transduction through clonal anergy.
|
Academic Article
|
A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3.
|
Academic Article
|
Expression and function of CTLA-4 in Th1 and Th2 cells.
|
Academic Article
|
Regulation of anti-immunoglobulin-induced B lymphoma growth arrest by transforming growth factor beta 1 and dexamethasone.
|
Academic Article
|
A phase II study of bryostatin-1 and paclitaxel in patients with advanced non-small cell lung cancer.
|
Academic Article
|
PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells.
|
Academic Article
|
Formation of a central supramolecular activation cluster is not required for activation of naive CD8+ T cells.
|
Academic Article
|
Lymphoma-infiltrating immune cells.
|
Academic Article
|
Farnesyltransferase inhibitors inhibit T-cell cytokine production at the posttranscriptional level.
|
Academic Article
|
Antiproliferative effect of IFN-gamma in immune regulation. III. Differential selection of TH1 and TH2 murine helper T lymphocyte clones using recombinant IL-2 and recombinant IFN-gamma.
|
Academic Article
|
Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment.
|
Academic Article
|
CD40 ligation reverses T cell tolerance in acute myeloid leukemia.
|
Academic Article
|
Phase II study of the Src kinase inhibitor saracatinib (AZD0530) in metastatic melanoma.
|
Academic Article
|
Cancer immunotherapy.
|
Academic Article
|
Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104).
|
Academic Article
|
Egr2-dependent gene expression profiling and ChIP-Seq reveal novel biologic targets in T cell anergy.
|
Academic Article
|
Targeting the tumor microenvironment with interferon-ß bridges innate and adaptive immune responses.
|
Academic Article
|
Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933.
|
Academic Article
|
Therapeutic activity of high-dose intratumoral IFN-ß requires direct effect on the tumor vasculature.
|
Academic Article
|
Conditional deletion of PTEN in peripheral T cells augments TCR-mediated activation but does not abrogate CD28 dependency or prevent anergy induction.
|
Academic Article
|
New perspectives on type I IFNs in cancer.
|
Academic Article
|
Primary murine CD4+ T cells fail to acquire the ability to produce effector cytokines when active Ras is present during Th1/Th2 differentiation.
|
Academic Article
|
STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors.
|
Academic Article
|
Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells.
|
Academic Article
|
Innate and adaptive immune cells in the tumor microenvironment.
|
Academic Article
|
The STING pathway and the T cell-inflamed tumor microenvironment.
|
Academic Article
|
Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints.
|
Academic Article
|
Melanoma-intrinsic ß-catenin signalling prevents anti-tumour immunity.
|
Academic Article
|
The Next Hurdle in Cancer Immunotherapy: Overcoming the Non-T-Cell-Inflamed Tumor Microenvironment.
|
Academic Article
|
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy.
|
Academic Article
|
Endogenous and pharmacologic targeting of the STING pathway in cancer immunotherapy.
|
Academic Article
|
Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.
|
Academic Article
|
Cutting Edge: Engineering Active IKKß in T Cells Drives Tumor Rejection.
|
Academic Article
|
Tumor and Host Factors Controlling Antitumor Immunity and Efficacy of Cancer Immunotherapy.
|
Academic Article
|
Molecular Drivers of the Non-T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer.
|
Academic Article
|
The composition of the microbiota modulates allograft rejection.
|
Academic Article
|
The host STING pathway at the interface of cancer and immunity.
|
Academic Article
|
Manipulating the microbiome to improve the efficacy of immunotherapy.
|
Academic Article
|
NK Cells Restrain Spontaneous Antitumor CD8+ T Cell Priming through PD-1/PD-L1 Interactions with Dendritic Cells.
|
Academic Article
|
Density of immunogenic antigens does not explain the presence or absence of the T-cell-inflamed tumor microenvironment in melanoma.
|
Academic Article
|
The EGR2 targets LAG-3 and 4-1BB describe and regulate dysfunctional antigen-specific CD8+ T cells in the tumor microenvironment.
|
Academic Article
|
Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy.
|
Academic Article
|
Impact of oncogenic pathways on evasion of antitumour immune responses.
|
Academic Article
|
The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients.
|
Academic Article
|
Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab.
|
Academic Article
|
Improving Efficacy and Safety of Agonistic Anti-CD40 Antibody Through Extracellular Matrix Affinity.
|
Academic Article
|
Back from the dead: TIL apoptosis in cancer immune evasion.
|
Academic Article
|
Intratumoral CD8+ T-cell Apoptosis Is a Major Component of T-cell Dysfunction and Impedes Antitumor Immunity.
|
Academic Article
|
Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancer.
|
Academic Article
|
Cancer Immunotherapy Targets Based on Understanding the T Cell-Inflamed Versus Non-T Cell-Inflamed Tumor Microenvironment.
|
Academic Article
|
Tumor heterogeneity and clonal cooperation influence the immune selection of IFN-?-signaling mutant cancer cells.
|
Academic Article
|
cDC1 dysregulation in cancer: An opportunity for intervention.
|
Academic Article
|
Epigenetic Control of Cdkn2a.Arf Protects Tumor-Infiltrating Lymphocytes from Metabolic Exhaustion.
|
Academic Article
|
Wilms tumor reveals DNA repair gene hyperexpression is linked to lack of tumor immune infiltration.
|
Academic Article
|
Antibody and T cell responses to COVID-19 vaccination in patients receiving anticancer therapies.
|
Academic Article
|
CXCL9 and CXCL10 bring the heat to tumors.
|
Academic Article
|
Batf3+ DCs and the 4-1BB/4-1BBL axis are required at the effector phase in the tumor microenvironment for PD-1/PD-L1 blockade efficacy.
|
Academic Article
|
Immunotherapy-activated T cells recruit and skew late-stage activated M1-like macrophages that are critical for therapeutic efficacy.
|